What is NDC 72606-037?

72606-037 is the product NDC for Stoboclo (denosumab-bmwo), Denosumab 60 mg/mL injection, listed with the FDA by CELLTRION USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

CELLTRION USA, Inc., NDC labeler code 72606. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Stoboclo?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Yes: J0897, Injection, denosumab, 1 mg.

Stoboclo NDC 72606-037 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72606-037Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72606-0037Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72606-037-01	72606003701	1 SYRINGE in 1 CARTON (72606-037-01) / 1 mL in 1 SYRINGEMarketed from Jul 2, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Stoboclo
Generic name (nonproprietary): denosumab-bmwo
Active ingredients: Denosumab — 60 mg/mL
Dosage form: Injection
Route: Subcutaneous
Labeler: CELLTRION USA, Inc.NDC labeler code 72606
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761404
Marketing start: Jul 2, 2025
Listing expires: Dec 31, 2027
Other FDA classes: RANK Ligand Blocking Activity (Mechanism)
Identifiers: Product ID 72606-037_a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49fSPL ID a1cd4ff2-cdab-41fa-b8f5-e2bc0faea49fSPL set ID 10b9eea3-bf70-4ff3-a0b9-54248cbfd156RxCUI 2717855, 2717862UNII 4EQZ6YO2HIUPC 0372606037019
Pharmacologic class: RANK Ligand Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0897 — Injection, denosumab, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

Denosumab biosimilars have their own HCPCS codes.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472606003701 followed by a unit qualifier and the quantity

Package 72606-0037-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 5, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture ( 1.3 ) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer ( 1.4 ) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer ( 1.5 ) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Stoboclo is indicated for the treatm…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72606-037

What is NDC 72606-037?: 72606-037 is the product NDC for Stoboclo (denosumab-bmwo), Denosumab 60 mg/mL injection, listed with the FDA by CELLTRION USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Stoboclo (Denosumab-bmwo).
What is the active ingredient?: Denosumab.
Who is the labeler?: CELLTRION USA, Inc., NDC labeler code 72606. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Stoboclo?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Yes: J0897, Injection, denosumab, 1 mg. See Billing references above.

Other NDCs under BLA 761404

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761404
Product	Strength	Form · route	Labeler	Product NDC
Denosumab-BMWO	Denosumab 60 mg/mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-058
Denosumab-BMWO	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-059
Osenveltdenosumab-bmwo	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-038

Stoboclo (Denosumab-bmwo) NDC 72606-037